Discover an SMA treatment that’s delivered directly to the central nervous system to
target an underlying cause of motor neuron loss in SMA3,8,9

How does SPINRAZA work?

SPINRAZA is a modified antisense oligonucleotide designed to target an underlying cause of motor neuron loss in SMA3

Explore the MOA
Data and Safety Profile

SPINRAZA has more than 8 years of clinical trial follow-up10

Safety Profile
Dedicated Patient Support

If patients or caregivers are experiencing nonmedical barriers to accessing treatment–such as the cost of SPINRAZA–Biogen may be able to help

View Support

Extensive real-world experience across a broad range of ages11

have been treated with
SPINRAZA worldwide11†

there’s someone from almost every
age group who has taken

have been treated with
SPINRAZA worldwide11†

Based on commercial patients, early access patients, and clinical trial participants through September 2023.11
SPINRAZA clinical studies included patients from 3 days to 16 years of age at first dose and did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger patients. Pivotal studies did not include adult patients.3

a later-onset SMA who is being treated with SPINRAZA

“Around age 32, I had moved across the country and started working with a new doctor. I was feeling weaker but learning to accept it. My doctor mentioned a treatment to me called SPINRAZA.” —Ian